Back to Search
Start Over
Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty
- Source :
- Blood Coagulation & Fibrinolysis, 25, 107-13, Blood Coagulation & Fibrinolysis, 25, 2, pp. 107-13
- Publication Year :
- 2014
-
Abstract
- Item does not contain fulltext Acute coronary syndromes (ACSs) represent a high-risk condition, as enhanced platelet reactivity importantly influences myocardial perfusion and procedural results after percutaneous coronary intervention (PCI). In fact, higher rate of periprocedural myocardial infarction (PMI) and reduced event-free survival have been reported in these patients. The single nucleotide polymorphism Leu33Pro of platelet glycoprotein IIIa has been related to an increased platelet reactivity, a lower response to antiplatelet agents and higher risk of stent restenosis. Therefore, our aim was to evaluate the impact of this polymorphism on PMI in patients undergoing PCI for non-ST-segment elevation MI (NSTEMI). Our population is represented by 478 consecutive patients undergoing coronary angioplasty for NSTEMI. Cardiac biomarkers were monitored at intervals from 8 to 48 h after the procedure. Genetic analysis was performed to assess the presence of Leu33Pro polymorphism. A total of 156 patients (32.6%) were polymorphic. Clinical features did not differ according to genetic status, neither pharmacological treatment pre and during angioplasty. PlA carriers had lower rate of calcifications (P = 0.01) and higher coronary tortuosity (P = 0.03) at angiography and underwent more frequently to thrombectomy (P = 0.05). PCI-related complications did not differ according to genotype. Leu33Pro polymorphism was not associated with increased risk of periprocedural myonecrosis and PMI even after correction for baseline differences, [odds ratio (OR) (95% confidence interval (CI) = 0.70 (0.44-1.13), P = 0.15 for PMI and OR (95% CI) = 0.77 (0.53-1.11), P = 0.17 for myonecrosis, respectively]. Results were confirmed in high-risk subgroups of patients. In conclusion, among patients undergoing PCI for ACS, the polymorphism Leu33Pro of platelet glycoprotein IIIa is not associated with increased risk of PMI.
- Subjects :
- Male
medicine.medical_specialty
medicine.medical_treatment
Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]
Population
Myocardial Infarction
periprocedural myonecrosi
Polymorphism, Single Nucleotide
glycoprotein IIbIIIa
Risk Factors
Internal medicine
Angioplasty
medicine
Humans
Genetic Predisposition to Disease
Myocardial infarction
Acute Coronary Syndrome
Angioplasty, Balloon, Coronary
education
Aged
platelet
education.field_of_study
medicine.diagnostic_test
business.industry
Risk Factor
Integrin beta3
Percutaneous coronary intervention
General Medicine
Odds ratio
Hematology
medicine.disease
Confidence interval
Angiography
Conventional PCI
Cardiology
Female
business
Human
Subjects
Details
- ISSN :
- 14735733 and 09575235
- Volume :
- 25
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
- Accession number :
- edsair.doi.dedup.....089fe5bfb07033f6fed1d7927191f5e7